Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?

Novo Nordisk (NVO) terminated its partnership with Hims & Hers (HIMS) over safety concerns regarding HIMS's use of compounded Wegovy versions, citing unapproved semaglutide sourcing from China and risky promotional tactics, which caused HIMS stock to crash 34.6%. This strategic shift, while temporarily impacting NVO's direct-to-patient access goals for Wegovy, reaffirms its commitment to patient safety and market integrity. NVO is now seeking new telehealth partners and benefits from CVS Caremark's recent designation of Wegovy as its preferred GLP-1 therapy, positioning it to compete against Eli Lilly's Zepbound in the rapidly evolving obesity market despite its own recent stock underperformance.

Analysis

Novo Nordisk (NVO) has terminated its Wegovy distribution partnership with Hims & Hers Health (HIMS), citing significant patient safety risks associated with HIMS's use of custom-compounded semaglutide from unapproved foreign suppliers and its promotional tactics. This decision led to a sharp 34.6% decline in HIMS stock. For NVO, this move represents a strategic trade-off, prioritizing long-term brand integrity and patient safety over a short-term sales channel. While this creates a temporary disruption to its direct-to-patient access goals and may slow market share gains against key competitor Eli Lilly (LLY), the impact is partially mitigated by a new agreement with CVS Caremark. Effective July 1, CVS will designate Wegovy as its preferred GLP-1 therapy for weight loss, a significant commercial advantage. This strategic pivot occurs amid a challenging backdrop for NVO, which has seen its stock underperform year-to-date with an 18.9% loss, faced pipeline setbacks with its CagriSema drug, and confronts increasing competition from LLY's Zepbound and emerging players like Viking Therapeutics. Despite these pressures, NVO's financials show a strong trailing 12-month return on equity of 80.95%, and while its forward P/E of 16.56 is a premium to the industry, it remains well below its five-year average of 29.25, suggesting a potential valuation disconnect.

Key Decisions for Investors

• Investors should weigh the near-term negative impact of the lost Hims & Hers sales channel against the long-term strategic benefit of protecting Wegovy's brand integrity and pricing power.
• Monitor the sales impact following July 1, when CVS Caremark's designation of Wegovy as a preferred therapy could provide a significant new commercial tailwind and offset the loss of the HIMS partnership.
• Closely track competitive developments, particularly sales data for Eli Lilly’s Zepbound and clinical progress from rivals like Viking Therapeutics, as the obesity market landscape is highly dynamic and directly impacts NVO's growth outlook.
• Consider NVO's current valuation, which is below its historical average, and its high return on equity as potential entry points, but be mindful of the stock's technical weakness, trading below its 200-day moving average, and mixed analyst estimate revisions for 2025 and 2026.